Biomarkers of sensitivity to potent and selective antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203) in ovarian cancer

Journal of Cellular Biochemistry

Volumn 114, Issue 10, 2013, Pages 2392-2404

  Callero, Mariana A ^a,b   Luzzani, Gabriela A ^a   De Dios, Diana O ^b   Bradshaw, Tracey D ^c   Loaiza Perez, Andrea I ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

5F203; AhR; CYP1A1; OVARIAN CANCER; ROS

Indexed keywords

2 (4 AMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE; BENZOTHIAZOLE DERIVATIVE; BIOLOGICAL MARKER; CYTOCHROME P450 1A1; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; OXIDATIVE STRESS; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 84882392664     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24589     Document Type: Article

References (37)

1. Bazzi R, Bradshaw TD, Rowlands C, Stevens MFG, Bell D,. 2009. 2-(4-Amino-3-methylphenyl)-5-fluorobenzothiazole is a ligand and shows species-specific partial agonism of the aryl hydrocarbon receptor. Toxicol Appl Pharmacol 237: 102-110.
2. Berghard A, Gradin K, Pongratz I, Whitelaw M, Poellinger L,. 1993. Cross-coupling of signal transduction pathways: The dioxin receptor mediates induction of cytochrome P-450IA1 expression via a protein kinase C-dependent mechanism. Mol Cell Biol 13: 677-689.
3. Bradshaw TD, Shi D-F, Schultz RJ, Paull KD, Kelland L, Wilson A, Garner C, Fiebig HH, Wrigley S, Stevens MF,. 1998. Influence of 2-(4-aminophenyl) benzothiazoles on growth of human ovarian carcinoma cell lines in vitro and in vivo. Br J Cancer 78: 421-429.
4. Bradshaw TD, Bibby MJ, Double JA, Fitchner I, Cooper PA, Alley MC, Donohue S, Stinson SF, Tomaszewiski JE, Sausville EA, Stevens MF,. 2000. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 1: 239-246.
5. Bradshaw TD, Bibby MJ, Double JA, Fitchner I, Cooper PA, Alley MC, Donohue S, Stinson SF, Tomaszewiski JE, Sausville EA, Stevens MF,. 2002. Preclinicalevaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 1: 239-246.
6. Bradshaw TD, Stone EL, Trapani V, Leong C-O, Matthews CS, te Poele R, Stevens MF,. 2008. Mechanisms of acquired resistance to 2-(4-amino-3- methylphenyl)benzothiazole in breast cancer cell lines. Breast Cancer Res Treat 110: 57-68.
7. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F,. 2001. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92: 738-747.
8. Chomczynski P, Sacchi N,. 1987. Single-step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
9. Fichtner I, Monks A, Hose C, Stevens MFG, Bradshaw TD,. 2004. The experimental antitumor agent Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models. Breast Cancer Res Treat 87: 97-107.
10. Hestermann EV, Brown M,. 2003. Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol 23: 7920-7925.
11. Hose CD, Hollingshead M, Sausville EA, Monks A,. 2003. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5- fluoro-benzothiazole: A potential surrogate marker for patient sensitivity. Mol Cancer Ther 2: 1265-1272.
12. Hutchinson I, Chua M-S, Browne HL, Trapani V, Bradshaw TD, Westwell AD, Stevens MF,. 2001. The synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44: 1446-1455.
13. Ikuta T, Eguchi H, Tachibana T, Yoneda Y, Kawajiri K,. 1998. Nuclear localization and export signals of the human aryl hydrocarbon receptor. J Biol Chem 273: 2895-2904.
14. Ikuta T, Tachibana T, Watanabe J, Yoshida M, Yoneda Y, Kawajiri K,. 2000. Nucleocytoplasmic shuttling of the aryl hydrocarbon receptor. J Biochem 127: 503-509.
15. Lin X, Li Q, Wang YJ, Ju YW, Chi ZQ, Wang MW, Liu JG,. 2007. Morphine inhibits doxorubicin-induced reactive oxygen species generation and nuclear factor kappaB transcriptional activation in neuroblastoma SH-SY5Y cells. Biochem J 406: 215-221.
16. Leong C-O, Suggitt M, Swaine MJ, Bibby MC, Stevens MFG, Bradshaw TD,. 2004. In vitro, in vivo and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Therap 3: 1565-1575.
17. Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel JB, Stevens MFG, Bradshaw TD, Sausville EA,. 2002. Aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 61: 13-19.
18. Ma Q, Baldwin KT,. 2000. 2,3,7,8-tetrachloro-dibenzo-p-dioxin-degradation of the aryl hydrocarbon receptor (AhR) by the ubiquitin proteosome-pathway. J Bio Chem 275: 8432-8438.
19. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, Nicolas A, Meyniel J-P, Cottu P, Sastre-Garau X, Mechta-Grigoriou F,. 2011. miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med 17: 1627-1635.
20. Mc Kinney M, Robbins M,. 1992. Chronic atropine administration up-regulatesrat-cortical muscarinic m1 receptor mRNA molecules: Assessment with the RT/PCR. Brain Res Mol Brain Res 12: 39-45.
21. McLean L, Davis W, Jr., Sowers E, Brantley EJ,. 2006. 5F 203-induced apoptosis involves oxidative stress and caspase activation in sensitive breast cancer cells. Washington DC, USA: American Association for Cancer Research (AACR).
22. Morgan MJ, Liu Z,. 2011. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 21: 103-115.
23. Nordeen SK,. 1998. Luciferase reporter gene vectors for analysis of promoter and enhancers. Biotechniques 6: 454-457.
24. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F,. 1996. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562.
25. Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F,. 1999. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection. Cell Growth Differ 10: 473-478.
26. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM,. 2000. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Bio Chem 275: 9390-9395.
27. Romero I, Bast RC, Jr., 2012. Minireview-Human ovarian cancer: Biology, current management, and paths to personalizing therapy. Endocrinology 153: 1593-1602.
28. Rowlands CJ, Staskal DF, Gollapudi B, Budinsky R,. 2010. The human AHR: Identification of single nucleotide polymorphisms from six ethnic populations. Pharmacogenet Genomics 20: 283-290.
29. Sanada N, Gotoh Y, Shimazawa R, Klinge CM, Kizu R,. 2009. Repression of activated aryl hydrocarbon receptor-induced transcriptional activation by 5α-dihydrotestosterone in human prostate cancer LNCaP and human breast cancer T47D Cells. J Pharmacol Sci 109: 380-387.
30. Shepherd TG, Thériault BL, Campbell EJ, Nachtigal MW,. 2006. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Prot 1: 2643-2649.
31. Tandon VR, Sharma S, Mahajan A, Bardi GH,. 2005. Oxidative stress: Novel strategy in cancer treatment. JK Sci 7: 1-3.
32. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ,. 2012. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS ONE 7; 1: e29079. doi: 10.1371/journal.pone.0029079
33. Vibhuti A, Arif E, Mishra A, Deepak D, Singh B, Rahman I, Mohammad G, Qadar Pasha MA,. 2010. CYP1A1, CYP1A2, and CYBA gene polymorphisms associated with oxidative stress in COPD. Clin Chim Acta 411: 474-480.
34. Wang K, Guengerich FP,. 2012. Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1. Chem Res Toxicol 25: 1740-1751.
35. Zheng Q, Sha X, Liu J, Heath E, Lorusso P, Li J,. 2010. Association of human cytochrome P450 1A1 (CYP1A1) and sulfotransferase 1A1 (SULT1A1) polymorphisms with differential metabolism and cytotoxicity of aminoflavone. Mol Cancer Ther 9: 2803-2813.
36. Ziech D, Franco R, Pappa A, Panayiotidis MI,. 2011. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res 711: 167-173.
37. Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, Zanier R, Giordano VG,. 2004. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST 1926, an atypical retinoid. Cell Death Differ 11: 280-289.